Trials / Completed
CompletedNCT02274181
An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Repros Therapeutics Inc. · Industry
- Sex
- Male
- Age
- 19 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the route(s) of elimination and mass balance of enclomiphene after oral administration of a single 25 mg (approximately equivalent to \[(\~\]) 500 nanocurie \[nCi\]) dose of \[14C\]Androxal in healthy adult male subjects.
Detailed description
The purpose of this study is to investigate the route(s) of elimination and mass balance of enclomiphene after oral administration of a single 25 mg (approximately equivalent to \[(\~\]) 500 nanocurie \[nCi\]) dose of \[14C\]Androxal in healthy adult male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Androxal |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2014-10-24
- Last updated
- 2015-03-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02274181. Inclusion in this directory is not an endorsement.